Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07555691

Yishen Shujin Decoction for Fibromyalgia Syndrome

This 24-week prospective study (12-week intervention + 12-week follow-up) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the therapeutic effects of YishenShujin Decoction, a clinically established herbal prescription, in patients with fibromyalgia (FM). The primary outcome is pain intensity measured by the Brief Pain Inventory (BPI). Secondary outcomes include improvements in the Fibromyalgia symptom scale(FS), revised Fibromyalgia Impact Questionnaire(FIQR), the Short Form-36 Health Status Questionnaire (SF-36), and FM-associated comorbidities. Safety profiles will be systematically monitored. In addition, brain structural and functional MRI will be used in this study to explore the underlying mechanisms.The findings aim to establish evidence for the formula's efficacy and provide insights into its role in FM management.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Beijing, Beijing Municipality, China

Location status: Recruiting

Location contact

Juan Jiao

CONTACT

[email protected]

8618611511082

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with primary fibromyalgia who met the FM classification criteria established by the American College of Rheumatology in 2016.
  • TCM syndromes of liver qi stagnation and yin blood insufficiency, or hepatic and renal yin deficiency.
  • aged 18 years old and above, 75 years old and below.
  • pain VAS score ≥ 4.
  • not taking the treatment of FM drugs or not using the treatment of FM program for more than 1 month.
  • Sign the informed consent.

Exclusion criteria

  • Patients with severe depression or anxiety ;
  • patients with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases and thrombotic diseases ;
  • Lactating or pregnant women ;
  • patients with allergy to therapeutic ingredients ;
  • patients with severe pain caused by other diseases ( such as diabetic pain or postherpetic neuralgia ) ;
  • patients who have recently participated in clinical trials of the same indications ;
  • Patients who are male, right-handed, or have contraindications for MRI will not undergo MRI scanning.

Contraindications include:

History of neurological diseases: brain tumor, stroke, epilepsy, traumatic brain injury, multiple sclerosis, etc.

Incompatible implants: cardiac pacemaker, defibrillator, certain types of aneurysm clips, cochlear implants, neurostimulators, etc.

Presence of metallic foreign bodies in the body: dentures, intraorbital metallic fragments, shrapnel in certain body regions, etc.

Claustrophobia.

Treatment and study plan

YishenShujin Decoction

Drug

Patients in the YishenShujin Decoction group received YishenShujin Decoction at a dose of 2 bags each time, twice daily for 12 weeks.

Placebo

Drug

The placebo was contained one-tenth of the dose of the original recipe. It was packaged in the same granule bag as the YishenShujin Decoction, ensuring that the placebo exhibited the same color, texture, taste, and smell as the actual medicine. Patients in the placebo group received placebo granule at a dose of 2 bags each time, twice daily for 12 weeks.

Primary outcomes

  1. The change of the Brief Pain Inventory (BPI) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    The Brief Pain Inventory (BPI) evaluates the severity of pain and pain-related interference with daily functioning. The BPI total and subscale scores range from 0 to 10, with higher scores indicating greater pain intensity and more significant interference with daily activities.

Secondary outcomes

  1. The change of Fibromyalgia Symptom Scale scores (Widespread Pain Index [WPI] and Symptom Severity Score [SSS]) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    This scale consists of two subdomains to evaluate the overall severity of fibromyalgia according to the ACR fibromyalgia diagnostic criteria.

    The Widespread Pain Index (WPI) assesses the extent and diffuseness of body pain, with scores ranging from 0 to 19. Higher scores indicate more widespread, diffuse pain distribution across the body.

    The Symptom Severity Score (SSS) evaluates the severity of core accompanying fibromyalgia symptoms, with total scores ranging from 0 to 12. Higher scores represent greater severity of general somatic and associated symptomatic burden.

  2. The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    A self-administered questionnaire with 10 subscales, measuring fibromyalgia symptoms and function domains. FIQR total score ranges from 0 to 100, with higher scores indicating more severe symptoms.

  3. The change of the Multidimensional Fatigue Inventory-20 (MFI-20) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    The Multidimensional Fatigue Inventory-20 (MFI-20) measures fatigue severity. The MFI-20 total score ranges from 0 to 80, with higher scores indicate more severe fatigue.

  4. The change of the Beck II Depression Inventory(BDI) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    The Beck II Depression Inventory (BDI) assesses the severity of depressive symptoms. Scores range from 0 to 39, with higher scores indicate a greater degree of depression severity.

  5. The change of the Perceived Stress Scale (PSS) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    The Perceived Stress Scale (PSS) is for measuring the perception of stress and current levels of experienced stress. Scores range from 0 to 56, with higher total score indicating a greater degree of symptom severity.

  6. The change of the Short Form-36 Health Status Questionnaire (SF-36) from baseline.

    Time frame: Baseline, week 2, week 4, week 8, week 12 and week 24

    The Short Form-36 Health Status Questionnaire (SF-36), which measured health-related quality of life (range, 0 to 100, with higher scores indicating better perceived health status).

  7. Global Impression of Change (PGIC) questionnaire evaluated at week 12.

    Time frame: Week 12.

    A questionnaire determine any change in overall symptom status from the beginning of the study to its conclusion (score range, 1 [very much improved] to 7 [very much worse).

  8. Brain morphology measured by structural MRI

    Time frame: Before and at the end of the study ( 0, 12 weeks ).

    To compare the changes in brain structure and morphology in patients with fibromyalgia before and after treatment by structural MRI. The images were acquired by a Siemens 3.0T Skyra scanner (Siemens; Munich, Germany) using fast spoiled gradient-echo sequence. Images contain whole brain, grey matter, white matter, atlas-based regions of interest for the patient group and healthy controls. The structural MRI images were processed with CAT 12 software (Version12.7, r1700). In detail, the voxel-based morphometry pipeline includes initial and refined voxel-based processing.

  9. Brain functional connectivity measured by function MRI

    Time frame: Before and at the end of the study ( 0, 12 weeks ).

    To compare the changes in connectivity and metabolic function of the brain in patients with fibromyalgia before and after treatment by function MRI. The scanning sequence is set up under the guidance of an imaging professional, while ensuring that the participants undergo the MRI scans with their eyes closed but awake; head movements do not exceed 1.5 mm in translation in any direction and 1.5° in rotation in any direction.

  10. Serum concentrations of inflammatory cytokines, oxidative stress biomarkers and circulating bile acids

    Time frame: Before and at the end of the study ( 0, 12 weeks ).

    Serum IL-6, TNF-α, HMGB1 were tested by ELISA; serum MDA, GSH were detected using biochemical colorimetric method; circulating bile acid components were quantified with liquid chromatography-mass spectrometry (LC-MS). All blood samples were collected at baseline (0 week) and study endpoint (12 weeks).

  11. Fecal relative abundance of intestinal microbiota, fecal bile acid concentration and fecal short-chain fatty acid concentration

    Time frame: Before and at the end of the study ( 0, 12 weeks ).

    Intestinal flora composition was profiled by 16S rRNA high-throughput sequencing; fecal bile acids and short-chain fatty acids were both determined via LC-MS/MS technology. Fecal specimens were collected at baseline (0 week) and study endpoint (12 weeks).

Study contacts

Contact information is provided by the study sponsor or research team.

Juan Jiao

CONTACT

[email protected]

010-88001132

Sponsors and collaborators

Lead sponsor

Juan Jiao

Other

Registry information

Official study title

A Randomized Controlled Clinical Trial and Mechanistic Investigation of Yishen Shujin Decoction for Fibromyalgia Syndrome

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 29, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.